All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of myocardial infarction (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of suspected serious drug reactions (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
12MWT: change from baseline in m walked · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
3MSC: change in 3MSC rates (stairs/min) from baseline · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
6MWT: change from baseline in m walked · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
Respiratory tests: absolute change from baseline in FVC (L) · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
Cardiac function  · children and adults with mucopolysaccharidosis type VI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
GAG level: change in urinary GAG level from baseline ųg/mg creatinine · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
AEs: drug‐related AEs · children and adults with mucopolysaccharidosis type VI
It is very uncertain whether the intervention changes AEs: drug‐related AEs (very low certainty).
1 finding from 1 review
Circuit lifespan · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from any cause at day 28 of · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery of kidney function · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vascular access complications · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Circuit lifespana · AKI patients receiving CKRT
1 finding from 1 review